Evidence map›Paper›PMID 33803793›Full record

ArticleInternational journal of molecular sciences2021

New Class of Anti-Inflammatory Therapeutics Based on Gold (III) Complexes in Intestinal Inflammation-Proof of Concept Based on In Vitro and In Vivo Studies.

Julia B Krajewska, Jakub Włodarczyk, Damian Jacenik, Radzisław Kordek, Przemysław Taciak, Remigiusz Szczepaniak, Jakub Fichna

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Metal Complexes in Diagnosis and Therapy.International journal of molecular sciences · 2022
    Article
  5. Review
  6. Article
  7. Gold (III) Derivatives in Colon Cancer Treatment.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Julia B KrajewskaDepartment of Biochemistry, Faculty of Medicine, Medical University of Lodz, 92-215 Lodz, Poland.
Jakub WłodarczykDepartment of Biochemistry, Faculty of Medicine, Medical University of Lodz, 92-215 Lodz, Poland.ORCID 0000-0003-2010-5136
Damian JacenikDepartment of Cytobiochemistry, University of Lodz, 90-236 Lodz, Poland.ORCID 0000-0003-4563-2303
Radzisław KordekDepartment of Pathology, Faculty of Medicine, 92-213 Lodz, Poland.
Przemysław TaciakDepartment of Pharmacodynamics, Faculty of Pharmacy, Medical University of Warsaw, 02-097 Warsaw, Poland.
Remigiusz SzczepaniakInwex Ltd., 25-323 Kielce, Poland.
Jakub FichnaDepartment of Biochemistry, Faculty of Medicine, Medical University of Lodz, 92-215 Lodz, Poland.ORCID 0000-0002-8443-4417
Medical University of Lodz · PLMedical University of Warsaw · PLUniversity of Łódź · PL

Funding

Medical University of Lodz #503/1-156-04/503-11-001-19National Science Center #UMO-2017/25/B/NZ5/02848
6 · The paper itself

Abstract

Inflammatory bowel diseases (IBD) are at the top of the worldwide rankings for gastrointestinal diseases as regards occurrence, yet efficient and side-effect-free treatments are currently unavailable. In the current study, we proposed a new concept for anti-inflammatory treatment based on gold (III) complexes. A new gold (III) complex TGS 121 was designed and screened in the in vitro studies using a mouse macrophage cell line, RAW264.7, and in vivo, in the dextran sulphate sodium (DSS)-induced mouse model of colitis. Physicochemical studies showed that TGS 121 was highly water-soluble; it was stable in water, blood, and lymph, and impervious to sunlight. In lipopolysaccharide (LPS)-stimulated RAW264.7 cells, the complex showed a potent anti-inflammatory profile, as evidenced in neutral red uptake and Griess tests. In the DSS-induced mouse model of colitis, the complex administered in two doses (1.68 μg/kg, intragastrically, and 16.8 μg/kg, intragastrically, once daily) produced a significant (*

Indexed as

Proof of Concept StudyAnimalsAnti-Inflammatory AgentsAntioxidantsColitisColonDextran SulfateDisease Models, AnimalGoldInflammationIntestinesMacrophagesMiceMice, Inbred C57BLRAW 264.7 CellsTight JunctionsAnti-Inflammatory AgentsAntioxidantsDextran SulfateGoldcolitisgold (III) complexinflammatory bowel diseasesRAW264.7 macrophages

Identifiers

PMID33803793
PMCPMC8003307
OpenAlexW3138900166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.